Ann: Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade, page-36

Firstly, it's great to see an ann that answers all my questions.

In particular with Pixclara, the fact that they're discussing "likely scope of label indications" is important and I guess will affect the true TAM at market launch (assuming all approvals etc). I would guess, in this situation, you can't go faster than the FDA.

When it comes to revenue, Lantheus' earnings call is at the end of July so we'll see how things are going then. Having said that, in previous years for both Illucix and Pylarify, the big jumps in sales come in the March quarter (does everyone get prostate cancer at the beginning of the year??).

As is usually the way, how good a result this is depends on how you like to play with statistics. The 8% jump this quarter compares with 17% for the equivalent quarter last year. However, in absolute terms you're looking at an increase of US$9m vs US$11.4m increase in the same quarter last year. Another way of looking at it is to compare the last three June quarters: 13.4, 77.6, 124. In the previous FY, that's a 64.2m jump. This FY, that's a 46.6m jump.

Superficially, I'd say there's still some growth in there and I would guess that reaching US$700m annualised sales- so AU$1b - is not out of the question.